Integra LifeSciences Holdings (Nasdaq: IART ) reported earnings on Feb. 21. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share expanded. GAAP earnings per share expanded significantly.
Gross margins were steady, operating margins contracted, net margins grew.
Integra LifeSciences Holdings booked revenue of $214.4 million. The 14 analysts polled by S&P Capital IQ expected revenue of $215.9 million on the same basis. GAAP reported sales were 5.4% higher than the prior-year quarter's $203.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.78. The 16 earnings estimates compiled by S&P Capital IQ forecast $0.76 per share. Non-GAAP EPS of $0.78 for Q4 were 8.3% higher than the prior-year quarter's $0.72 per share. GAAP EPS of $0.46 for Q4 were 188% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 61.8%, much about the same as the prior-year quarter. Operating margin was 8.7%, 410 basis points worse than the prior-year quarter. Net margin was 6.0%, 380 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $206.0 million. On the bottom line, the average EPS estimate is $0.70.
Next year's average estimate for revenue is $871.3 million. The average EPS estimate is $3.19.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 155 members out of 164 rating the stock outperform, and nine members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.08.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.